Tag: Prescription access

Following a period of significant supply challenges that affected all doses, the U.S. Food and Drug Administration (FDA) formally declared the tirzepatide shortage resolved in December 2024, raising the question: are all doses of Zepbound available now? With expanded manufacturing and the introduction of new vial options, Eli Lilly has largely stabilized supply, though specific product formats and retail pharmacy stock can still vary.

According to the FDA, the tirzepatide shortage that affected Zepbound and Mounjaro was officially resolved in December 2024, yet availability at individual pharmacies can still vary based on demand. If you have a prescription and are wondering, 'How can I find out where Zepbound is available?', there are several proactive methods to locate your medication and maintain a consistent supply.

As of July 1, 2025, CVS Caremark removed Zepbound from its standard preferred formulary for many insurance plans, a decision that has caused significant confusion for millions of users. This policy change necessitates a clear understanding of the difference between a retail pharmacy and an insurance plan to properly answer the question: **Does CVS carry Zepbound**?.

Following its FDA accelerated approval in March 2024, Rezdiffra™ (resmetirom) became the first and only medication specifically approved for treating noncirrhotic nonalcoholic steatohepatitis (NASH). As a specialized treatment, Rezdiffra™ is not available at standard retail pharmacies, and obtaining it requires a specific process involving a prescription and a network of specialty pharmacies.